RMI Partners’s investment focus is novel biopharmaceutical products, medical technologies and diagnostic tools that can help extend human life and make it healthier and more productive. We firmly believe in the future of advanced technology and strive to support innovative projects that are success-oriented and provide adequate profits to the investors.

Our main investment criteria:

      * Novel breakthrough technology

                                                                    * Experienced team

                                                                    * Significant medical problem

                                                                    * Tangible commercial prospects in the market


  • 11 July 2018

    Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

    learside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Carol Hoang , Pharm.D., MBA, to the position of Vice President, Medical Affairs.

  • 10 July 2018

    Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

    An international team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Epic Sciences, The Institute of Cancer Research, UK, and London Health Sciences Centre, Canada, have shown that a blood test can identify patients with metastatic castration resistant prostate cancer (mCRPC) who may live longer if they switch from targeted androgen receptor-signaling inhibitor (ARSi) therapy, such as enzalutamide and abiraterone, to taxane-based chemotherapy. This independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.